Subcutaneous Methylnaltrexone as Treatment for Opioid-Induced Constipation in Patients with Advanced Cancer and Noncancer Illnesses: A Post Hoc Analysis of Two Clinical Trials

References

• van den Beuken-van Everdingen MH, Hochstenbach LM, Joosten EA, Tjan-Heijnen VC, Janssen DJ. Update on prevalence of pain in patients with cancer: systematic review and meta-analysis. J Pain Symptom Manage. 2016;51(6):1070–1090.e1079. doi:10.1016/j.jpainsymman.2015.12.340
   PubMed Web of Science ®Google Scholar
• Teunissen SC, Wesker W, Kruitwagen C, de Haes HC, Voest EE, de Graeff A. Symptom prevalence in patients with incurable cancer: a systematic review. J Pain Symptom Manage. 2007;34(1):94–104. doi:10.1016/j.jpainsymman.2006.10.015
   PubMed Web of Science ®Google Scholar
• Solano JP, Gomes B, Higginson IJ. A comparison of symptom prevalence in far advanced cancer, AIDS, heart disease, chronic obstructive pulmonary disease and renal disease. J Pain Symptom Manage. 2006;31(1):58–69. doi:10.1016/j.jpainsymman.2005.06.007
   PubMed Web of Science ®Google Scholar
• Glare P, Walsh D, Sheehan D. The adverse effects of morphine: a prospective survey of common symptoms during repeated dosing for chronic cancer pain. Am J Hosp Palliat Care. 2006;23(3):229–235. doi:10.1177/1049909106289068
   PubMedGoogle Scholar
• Cook SF, Lanza L, Zhou X, et al. Gastrointestinal side effects in chronic opioid users: results from a population-based survey. Aliment Pharmacol Ther. 2008;27(12):1224–1232. doi:10.1111/j.1365-2036.2008.03689.x
   Web of Science ®Google Scholar
• Rauck RL, Hong KJ, North J. Opioid-induced constipation survey in patients with chronic noncancer pain. Pain Pract. 2017;17(3):329–335. doi:10.1111/papr.12445
   PubMed Web of Science ®Google Scholar
• Pappagallo M. Incidence, prevalence, and management of opioid bowel dysfunction. Am J Surg. 2001;182(suppl5A):11S–18S. doi:10.1016/S0002-9610(01)00782-6
   Web of Science ®Google Scholar
• Kumar L, Barker C, Emmanuel A. Opioid-induced constipation: pathophysiology, clinical consequences, and management. Gastroenterol Res Pract. 2014;2014:1–6. doi:10.1155/2014/141737
   Web of Science ®Google Scholar
• Slatkin N, Thomas J, Lipman AG, et al. Methylnaltrexone for treatment of opioid-induced constipation in advanced illness patients. J Support Oncol. 2009;7(1):39–46.
   PubMedGoogle Scholar
• Yuan CS, Foss JF, O’Connor M, Toledano A, Roizen MF, Moss J. Methylnaltrexone prevents morphine-induced delay in oral-cecal transit time without affecting analgesia: a double-blind randomized placebo-controlled trial. Clin Pharmacol Ther. 1996;59(4):469–475. doi:10.1016/S0009-9236(96)90117-4
   PubMed Web of Science ®Google Scholar
• Galligan JJ, Akbarali HI. Molecular physiology of enteric opioid receptors. Am J Gastroenterol Suppl. 2014;2(1):17–21. doi:10.1038/ajgsup.2014.5
   PubMedGoogle Scholar
• Wickham RJ. Managing constipation in adults with cancer. J Adv Pract Oncol. 2017;8(2):149–161.
   PubMedGoogle Scholar
• Emmanuel A, Johnson M, McSkimming P, Dickerson S. Laxatives do not improve symptoms of opioid-induced constipation: results of a patient survey. Pain Med. 2017;18(10):1932–1940. doi:10.1093/pm/pnw240
   Web of Science ®Google Scholar
• Pergolizzi JV, Christo PJ, LeQuang JA, Magnusson P. The use of peripheral μ-opioid receptor antagonists (PAMORA) in the management of opioid-induced constipation: an update on their efficacy and safety. Drug Des Devel Ther. 2020;14:1009–1025. doi:10.2147/DDDT.S221278
   PubMed Web of Science ®Google Scholar
• Relistor [package insert]. Bridgewater, NJ: Salix Pharmaceuticals; 2018.
   Google Scholar
• Bull J, Wellman CV, Israel RJ, Barrett AC, Paterson C, Forbes WP. Fixed-dose subcutaneous methylnaltrexone in patients with advanced illness and opioid-induced constipation: results of a randomized, placebo-controlled study and open-label extension. J Palliat Med. 2015;18(7):593–600. doi:10.1089/jpm.2014.0362
   PubMed Web of Science ®Google Scholar
• Thomas J, Karver S, Cooney GA, et al. Methylnaltrexone for opioid-induced constipation in advanced illness. N Engl J Med. 2008;358(22):2332–2343. doi:10.1056/NEJMoa0707377
   PubMed Web of Science ®Google Scholar
• Chamberlain BH, Rhiner M, Slatkin NE, Stambler N, Israel RJ. Subcutaneous methylnaltrexone for treatment of opioid-induced constipation in cancer versus noncancer patients: an analysis of efficacy and safety variables from two studies. J Pain Res. 2021;14:2687–2697. doi:10.2147/JPR.S312731
   PubMed Web of Science ®Google Scholar
• Saini HS, Alvi Z, Singh B, Elsharkawy B, Yasir M. Methylnaltrexone and naloxone for opioid-induced constipation in the critical care setting. Cureus. 2020;12(1):e6829. doi:10.7759/cureus.6829
   Web of Science ®Google Scholar
• What is a serious adverse event? 2016. Available from: https://www.fda.gov/safety/reporting-serious-problems-fda/what-serious-adverse-event. Accessed February 15, 2022.
   Google Scholar
• Webster LR, Brenner DM, Barrett AC, Paterson C, Bortey E, Forbes WP. Analysis of opioid-mediated analgesia in phase III studies of methylnaltrexone for opioid-induced constipation in patients with chronic noncancer pain. J Pain Res. 2015;8:771–780. doi:10.2147/JPR.S88203
   Web of Science ®Google Scholar
• Michna E, Blonsky ER, Schulman S, et al. Subcutaneous methylnaltrexone for treatment of opioid-induced constipation in patients with chronic, nonmalignant pain: a randomized controlled study. J Pain. 2011;12(5):554–562. doi:10.1016/j.jpain.2010.11.008
   PubMed Web of Science ®Google Scholar
• Neefjes ECW, van der Wijngaart H, van der Vorst M, et al. Optimal treatment of opioid induced constipation in daily clinical practice - an observational study. BMC Palliat Care. 2019;18(1):31. doi:10.1186/s12904-019-0416-7
   Google Scholar
• Sanchez MI, Bercik P. Epidemiology and burden of chronic constipation. Can J Gastroenterol. 2011;25(Suppl B):11b–15b. doi:10.1155/2011/974573
   PubMedGoogle Scholar